These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
248 related articles for article (PubMed ID: 26412316)
1. High sensitivity for lung cancer detection using analysis of exhaled carbonyl compounds. Schumer EM; Trivedi JR; van Berkel V; Black MC; Li M; Fu XA; Bousamra M J Thorac Cardiovasc Surg; 2015 Dec; 150(6):1517-22; discussion 1522-4. PubMed ID: 26412316 [TBL] [Abstract][Full Text] [Related]
2. Normalization of Exhaled Carbonyl Compounds After Lung Cancer Resection. Schumer EM; Black MC; Bousamra M; Trivedi JR; Li M; Fu XA; van Berkel V Ann Thorac Surg; 2016 Oct; 102(4):1095-100. PubMed ID: 27293148 [TBL] [Abstract][Full Text] [Related]
3. Breath carbonyl compounds as biomarkers of lung cancer. Li M; Yang D; Brock G; Knipp RJ; Bousamra M; Nantz MH; Fu XA Lung Cancer; 2015 Oct; 90(1):92-7. PubMed ID: 26233567 [TBL] [Abstract][Full Text] [Related]
4. Quantitative analysis of exhaled carbonyl compounds distinguishes benign from malignant pulmonary disease. Bousamra M; Schumer E; Li M; Knipp RJ; Nantz MH; van Berkel V; Fu XA J Thorac Cardiovasc Surg; 2014 Sep; 148(3):1074-80; discussion 1080-1. PubMed ID: 25129599 [TBL] [Abstract][Full Text] [Related]
5. Quantitative breath analysis of volatile organic compounds of lung cancer patients. Song G; Qin T; Liu H; Xu GB; Pan YY; Xiong FX; Gu KS; Sun GP; Chen ZD Lung Cancer; 2010 Feb; 67(2):227-31. PubMed ID: 19409642 [TBL] [Abstract][Full Text] [Related]
6. Noninvasive detection of lung cancer using exhaled breath. Fu XA; Li M; Knipp RJ; Nantz MH; Bousamra M Cancer Med; 2014 Feb; 3(1):174-81. PubMed ID: 24402867 [TBL] [Abstract][Full Text] [Related]
7. Breath gas aldehydes as biomarkers of lung cancer. Fuchs P; Loeseken C; Schubert JK; Miekisch W Int J Cancer; 2010 Jun; 126(11):2663-70. PubMed ID: 19839051 [TBL] [Abstract][Full Text] [Related]
8. The analysis of volatile organic compounds biomarkers for lung cancer in exhaled breath, tissues and cell lines. Wang Y; Hu Y; Wang D; Yu K; Wang L; Zou Y; Zhao C; Zhang X; Wang P; Ying K Cancer Biomark; 2012; 11(4):129-37. PubMed ID: 23144150 [TBL] [Abstract][Full Text] [Related]
9. Determination of volatile organic compounds in exhaled breath of patients with lung cancer using solid phase microextraction and gas chromatography mass spectrometry. Ligor M; Ligor T; Bajtarevic A; Ager C; Pienz M; Klieber M; Denz H; Fiegl M; Hilbe W; Weiss W; Lukas P; Jamnig H; Hackl M; Buszewski B; Miekisch W; Schubert J; Amann A Clin Chem Lab Med; 2009; 47(5):550-60. PubMed ID: 19397483 [TBL] [Abstract][Full Text] [Related]
10. Observation of nonanoic acid and aldehydes in exhaled breath of patients with lung cancer. Callol-Sanchez L; Munoz-Lucas MA; Gomez-Martin O; Maldonado-Sanz JA; Civera-Tejuca C; Gutierrez-Ortega C; Rodriguez-Trigo G; Jareno-Esteban J J Breath Res; 2017 Apr; 11(2):026004. PubMed ID: 28440225 [TBL] [Abstract][Full Text] [Related]
11. Investigation of lung cancer biomarkers by hyphenated separation techniques and chemometrics. Buszewski B; Ulanowska A; Kowalkowski T; Cieśliński K Clin Chem Lab Med; 2011 Oct; 50(3):573-81. PubMed ID: 22035139 [TBL] [Abstract][Full Text] [Related]
12. Real-time ultrasensitive VUV-PIMS detection of representative endogenous volatile markers in cancers. Li Z; Shu J; Zhang P; Sun W; Yang B; Zhang H Cancer Biomark; 2016; 16(3):477-87. PubMed ID: 27062705 [TBL] [Abstract][Full Text] [Related]
13. Blinded Validation of Breath Biomarkers of Lung Cancer, a Potential Ancillary to Chest CT Screening. Phillips M; Bauer TL; Cataneo RN; Lebauer C; Mundada M; Pass HI; Ramakrishna N; Rom WN; Vallières E PLoS One; 2015; 10(12):e0142484. PubMed ID: 26698306 [TBL] [Abstract][Full Text] [Related]
14. Volatile signature for the early diagnosis of lung cancer. Gasparri R; Santonico M; Valentini C; Sedda G; Borri A; Petrella F; Maisonneuve P; Pennazza G; D'Amico A; Di Natale C; Paolesse R; Spaggiari L J Breath Res; 2016 Feb; 10(1):016007. PubMed ID: 26857451 [TBL] [Abstract][Full Text] [Related]
15. Confounding effect of benign pulmonary diseases in selecting volatile organic compounds as markers of lung cancer. Wang M; Sheng J; Wu Q; Zou Y; Hu Y; Ying K; Wan H; Wang P J Breath Res; 2018 Sep; 12(4):046013. PubMed ID: 30102249 [TBL] [Abstract][Full Text] [Related]
16. Ion mobility spectrometry for the detection of volatile organic compounds in exhaled breath of patients with lung cancer: results of a pilot study. Westhoff M; Litterst P; Freitag L; Urfer W; Bader S; Baumbach JI Thorax; 2009 Sep; 64(9):744-8. PubMed ID: 19158121 [TBL] [Abstract][Full Text] [Related]
17. Comparison of volatile organic compounds from lung cancer patients and healthy controls-challenges and limitations of an observational study. Schallschmidt K; Becker R; Jung C; Bremser W; Walles T; Neudecker J; Leschber G; Frese S; Nehls I J Breath Res; 2016 Oct; 10(4):046007. PubMed ID: 27732569 [TBL] [Abstract][Full Text] [Related]
18. Exhaled biomarkers in lung cancer. Horváth I; Lázár Z; Gyulai N; Kollai M; Losonczy G Eur Respir J; 2009 Jul; 34(1):261-75. PubMed ID: 19567608 [TBL] [Abstract][Full Text] [Related]
19. Breath testing as a method for detecting lung cancer. Taivans I; Bukovskis M; Strazda G; Jurka N Expert Rev Anticancer Ther; 2014 Feb; 14(2):121-3. PubMed ID: 24467216 [TBL] [Abstract][Full Text] [Related]
20. Progress in the development of volatile exhaled breath signatures of lung cancer. Mazzone PJ; Wang XF; Lim S; Jett J; Choi H; Zhang Q; Beukemann M; Seeley M; Martino R; Rhodes P Ann Am Thorac Soc; 2015 May; 12(5):752-7. PubMed ID: 25965541 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]